Fresenius Medical Care AG

NYSE:FMS Stock Report

Market Cap: US$13.7b

Fresenius Medical Care Management

Management criteria checks 2/4

Fresenius Medical Care's CEO is Helen Giza, appointed in Nov 2019, has a tenure of 5.08 years. total yearly compensation is €5.53M, comprised of 30.1% salary and 69.9% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth $641.26K. The average tenure of the management team and the board of directors is 2 years and 0.9 years respectively.

Key information

Helen Giza

Chief executive officer

€5.5m

Total compensation

CEO salary percentage30.1%
CEO tenure5.1yrs
CEO ownership0.005%
Management average tenure2yrs
Board average tenureless than a year

Recent management updates

Recent updates

Fresenius Medical Care: Let's Look At The Upside

Oct 04

Fresenius Medical Care: Significant Upside Remains

Jun 25

Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns

Feb 23

Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off

Oct 12

Fresenius Medical Care: Other Stocks Still Better, But Upside Exists

Jun 01

Fresenius Medical Care Q4 2022 Earnings Preview

Feb 21

Fresenius: The Company Is Climbing, And I'm At 'Buy'

Jan 06

Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)

Oct 27

Fresenius Medical gains after report of activist Elliott stake in Fresenius SE

Oct 19

Fresenius cut to Hold at Jefferies citing staffing issues and inflation

Oct 10

Fresenius gets award to provide dialysis services to U.S. military veterans

Aug 30

Fresenius appoints head of pharma unit as new CEO

Aug 19

Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat

Jul 30

Fresenius Medical Care accused of Medicare fraud in dialysis

Jul 13

Fresenius: The Upside Is Getting Bigger

May 02

You Really Want To Know About Fresenius Medical Care

Aug 28

Fresenius Medical drops 12% on disappointing 2021 outlook

Feb 02

Fresenius Medical Care EPS beats by €0.06, misses on revenue

Oct 29

CEO Compensation Analysis

How has Helen Giza's remuneration changed compared to Fresenius Medical Care's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

€659m

Jun 30 2024n/an/a

€530m

Mar 31 2024n/an/a

€484m

Dec 31 2023€6m€2m

€499m

Sep 30 2023n/an/a

€450m

Jun 30 2023n/an/a

€596m

Mar 31 2023n/an/a

€602m

Dec 31 2022€3m€1m

€673m

Sep 30 2022n/an/a

€763m

Jun 30 2022n/an/a

€806m

Mar 31 2022n/an/a

€878m

Dec 31 2021€2m€855k

€969m

Sep 30 2021n/an/a

€918m

Jun 30 2021n/an/a

€998m

Mar 31 2021n/an/a

€1b

Dec 31 2020€2m€855k

€1b

Sep 30 2020n/an/a

€1b

Jun 30 2020n/an/a

€1b

Mar 31 2020n/an/a

€1b

Dec 31 2019€2m€108k

€1b

Compensation vs Market: Helen's total compensation ($USD5.73M) is below average for companies of similar size in the US market ($USD12.63M).

Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.

CEO

Helen Giza (56 yo)

5.1yrs

Tenure

€5,528,000

Compensation

Ms. Helen Giza is Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from December 6, 2022. She serve...

Leadership Team

NamePositionTenureCompensationOwnership
Helen Giza
Chair of Management Board & CEO5.1yrs€5.53m0.0047%
$ 641.3k
Martin Fischer
CFO & Member of the Management Board1.2yrs€887.00kno data
Franklin Maddux
Global Chief Medical Officer & Member of Management Board4.9yrs€3.13m0.0062%
$ 846.8k
Katarzyna Mazur-Hofsab
CEO of Care Enablement & Member of Management Board2.9yrs€3.71m0.0039%
$ 530.3k
Craig Cordola
CEO of Care Delivery & Member of Management Boardless than a yearno datano data
Dominik Heger
Executive VP and Head of Investor Relationsno datano datano data
Jorg Haring
Global Head of Legalless than a yearno datano data
Joachim Weith
Senior Vice President of Corporate Communications & Governmental Affairsno datano datano data
Gail-Suzanne Brown
Senior Vice President of Research & Developmentno datano datano data
Glenn Slater
Senior Vice President of Manufacturing and Supply Chain Operationsno datano datano data
Wolfgang Kummerle
Senior Vice President - Quality Management Internationalno datano datano data
Thomos Dimt
Executive Vice President of Western Europe & Nephrocare Coordination EMEALAno datano datano data

2.0yrs

Average Tenure

56.5yo

Average Age

Experienced Management: FMS's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shervin Korangy
Independent Member of Supervisory Board1.1yrs€20.00kno data
Michael Sen
Chairman of the Supervisory Board1.4yrs€444.00kno data
Marcus Kuhnert
Independent Member of Supervisory Board1.1yrs€21.00kno data
A. Sorensen
Independent Member of Supervisory Board3.6yrs€151.00kno data
Stefanie Balling
Employee Representative Deputy Chairwoman of the Supervisory Boardless than a yearno datano data
Sara Hennicken
Member of Supervisory Board1.1yrs€158.00kno data
Frank Prescher
Employee Representative Member of Supervisory Boardless than a yearno datano data
Regina Karsch
Employee Representative Member of the Supervisory Boardless than a yearno datano data
Manuela Grabo
Employee Representative Member of the Supervisory Boardless than a yearno datano data
Ralf Erkens
Employee representatives Member of the Supervisory Boardless than a yearno datano data
Beate Habdenteufel
Employee representatives Member of the Supervisory Boardless than a yearno datano data

0.9yrs

Average Tenure

56yo

Average Age

Experienced Board: FMS's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:42
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresenius Medical Care AG is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martin SchneeAlphaValue
Brian WilliamsAvondale Partners
Olav ZilianBaader Helvea Equity Research